Please assess the completion status of the following clinical trial:

Trial Title: Chewing Versus Traditional Oral Administration of Ticagrelor in STEMI Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients presenting with STEMI~2. Informed, written consent~Exclusion Criteria:~1. Age \< 18 years or Age \> 90 years~2. Active bleeding; bleeding diathesis; coagulopathy~3. Increased risk of bradycardic events~4. History of gastrointestinal or genitourinary bleeding \<2 months~5. Major surgery in the last 6 weeks~6. History of intracranial bleeding or structural abnormalities~7. Suspected aortic dissection~8. Any other condition that may put the patient at risk or influence study results or investigator's opinion (severe hemodynamic instability, unconsciousness, known malignancies or other comorbid conditions with life expectancy \<1 year)~9. Administration in the week before the index event of clopidogrel, ticlopidine, prasugrel, ticagrelor, thrombolytics, bivalirudin, low-molecular weight heparin or fondaparinux.~10. Concomitant oral or IV therapy with strong CYP3A inhibitors or strong CYP3A inducers, CYP3A with narrow therapeutic windows~11. Known relevant hematological deviations: Hb \<10 g/dl, PLT\<100x10\^9/l~12. Use of coumadin derivatives within the last 7 days~13. Chronic therapy with ticagrelor, prasugrel, clopidogrel or ticlopidine~14. Known severe liver disease, severe renal failure~15. Known allergy to the study medications~16. Pregnancy~17. Human immunodeficiency virus treatment~18. The use of IIBIIIA receptor antagonists in the 48 hours before enrollment (if abciximab use then in the last 14 days).~19. If the patients cannot sign percutaneous coronary intervention (PCI) informed consent for any reason.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Oral Ticagrelor (Type: ACTIVE_COMPARATOR): None
- Chewing Ticagrelor (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).